A Novel Aβ B-Cell Epitope Vaccine (rCV01) for Alzheimer’s Disease Improved Synaptic and Cognitive Functions in 3 × Tg-AD Mice

Amyloid-β Induces Caspase-Dependent Loss of PSD-95 and Synaptophysin Through NMDA Receptors

(2017) Jinping Liu et al.   JOURNAL OF ALZHEIMERS DISEASE

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

(2015) Kirsten L. Viola et al.   ACTA NEUROPATHOLOGICA

Amyloid-β11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

(2015) Enchi Liu et al.   NEUROLOGY

Co-immunization with DNA and protein mixture: A safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice

(2015) Si Liu et al.   Scientific Reports

A framework to understand the variations of PSD-95 expression in brain aging and in Alzheimer's disease

(2014) Armand Savioz et al.   AGEING RESEARCH REVIEWS

Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer’s disease mouse model

(2014) Mario M. Dorostkar et al.   BRAIN

Pathological Reorganization of NMDA Receptors Subunits and Postsynaptic Protein PSD-95 Distribution in Alzheimer’s Disease

(2014) Genevieve Leuba et al.   Current Alzheimer Research

Is there still any hope for amyloid-based immunotherapy for Alzheimerʼs disease?

(2014) Francesco Panza et al.   CURRENT OPINION IN PSYCHIATRY

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

(2014) Francesco Panza et al.   Expert Review of Clinical Immunology

Amyloid-ß-directed immunotherapy for Alzheimer's disease

(2014) L. Lannfelt et al.   JOURNAL OF INTERNAL MEDICINE

IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology

(2014) Isabelle St-Amour et al.   Journal of Neuroinflammation

Hsp90 Chaperone Inhibitor 17-AAG Attenuates A -Induced Synaptic Toxicity and Memory Impairment

(2014) Y. Chen et al.   JOURNAL OF NEUROSCIENCE

Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease

(2014) Shichun Tu et al.   Molecular Neurodegeneration

Conformational targeting of intracellular Aβ oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum

(2014) Giovanni Meli et al.   Nature Communications

Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease

(2013) Maria C. Carrillo et al.   Alzheimers & Dementia

Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice

(2013) Suhail Rasool et al.   JOURNAL OF NEUROCHEMISTRY

Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease

(2013) Lydia Giménez-Llort et al.   mAbs

Calpain Inhibition as a Potential Treatment of Alzheimer's Disease

(2012) Godfrey S. Getz   AMERICAN JOURNAL OF PATHOLOGY

Calpain Inhibitor A-705253 Mitigates Alzheimer's Disease–Like Pathology and Cognitive Decline in Aged 3xTgAD Mice

(2012) Rodrigo Medeiros et al.   AMERICAN JOURNAL OF PATHOLOGY

Soluble A  Promotes Wild-Type Tau Pathology In Vivo

(2012) M. A. Chabrier et al.   JOURNAL OF NEUROSCIENCE

Targeting Synaptic Dysfunction in Alzheimer’s Disease Therapy

(2012) Robert Nisticò et al.   MOLECULAR NEUROBIOLOGY

Synaptic changes in Alzheimer’s disease and its models

(2012) J. Pozueta et al.   NEUROSCIENCE

Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer’s disease

(2011) Charles Y. Shao et al.   ACTA NEUROPATHOLOGICA

Immunotherapy for Alzheimer's Disease: Rational Basis in Ongoing Clinical Trials

(2011) Manuel Menendez-Gonzalez et al.   CURRENT PHARMACEUTICAL DESIGN

AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly

(2011) Sophie Sokolow et al.   NEUROBIOLOGY OF AGING

Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of Alzheimer's disease: a possible effect on APP processing

(2011) N C Inestrosa et al.   Translational Psychiatry

Murine models of Alzheimer's disease and their use in developing immunotherapies

(2010) Thomas Wisniewski et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

TAU Aggregation is a Therapeutic Target for Alzheimers Disease

(2010) A. Takashima   Current Alzheimer Research

Generation and Therapeutic Efficacy of Highly Oligomer-Specific  -Amyloid Antibodies

(2010) H. Hillen et al.   JOURNAL OF NEUROSCIENCE

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Vaccination as a Therapeutic Approach to Alzheimer's Disease

(2010) Thomas Wisniewski et al.   MOUNT SINAI JOURNAL OF MEDICINE

Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models

(2009) Thomas Wisniewski et al.   Brain Structure & Function

Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy

(2009) Anahit Ghochikyan   CNS & Neurological Disorders-Drug Targets

Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior

(2008) Dennis J. Selkoe   BEHAVIOURAL BRAIN RESEARCH

Reassessing the amyloid cascade hypothesis of Alzheimer's disease

(2008) Sanjay W. Pimplikar   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET

The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons

(2008) Roxana C. Sinjoanu et al.   NEUROCHEMISTRY INTERNATIONAL